Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
VOR - Vor Biopharma Inc.
Market Cap 199.53M P/E - EPS this Y 12.00% Ern Qtrly Grth -
Income -118.09M Forward P/E -1.61 EPS next Y 22.10% 50D Avg Chg -24.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -38.00%
Dividend N/A Price/Book 0.87 EPS next 5Y - 52W High Chg -61.00%
Recommedations 1.60 Quick Ratio 6.23 Shares Outstanding 68.40M 52W Low Chg 13.00%
Insider Own 1.18% ROA -39.74% Shares Float 32M Beta -0.34
Inst Own 81.04% ROE -78.07% Shares Shorted/Prior 2.54M/1.66M Price 2.98
Gross Margin - Profit Margin - Avg. Volume 220,090 Target Price 13.19
Oper. Margin - Earnings Date Nov 5 Volume 114,562 Change -5.99%
Healthcare | Biotechnology | United States
About Vor Biopharma Inc.

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma Inc. News
12/09/24 Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
11/07/24 Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
09/30/24 Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
09/05/24 New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
09/05/24 Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely
08/08/24 Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
08/02/24 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/09/24 Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
05/06/24 Vor Bio to Participate in Upcoming Investor Conferences
05/02/24 Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
04/04/24 Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
03/29/24 Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
03/20/24 Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
02/17/24 Institutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the company
02/15/24 2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)
02/07/24 Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/19/24 Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
01/17/24 Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
5AM Ventures VI, L.P. 10% Owner 10% Owner Nov 16 Sell 15.3 330,706 5,059,802 1,766,634 11/18/21
PARMAR KUSH Director Director Nov 16 Sell 15.3 330,706 5,059,802 1,766,634 11/18/21